← Back to Search

Proteasome Inhibitor

Carfilzomib for Disease

Phase 1 & 2

Waitlist Available

Led By Steven Horwitz, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is testing a new combination of drugs for patients with relapsed or refractory B- and T-cell lymphomas. The maximum tolerated dose will be determined in the first part of the trial, and then the trial will expand to include more patients at that dose to better understand the efficacy of the combination.

Eligible Conditions

Disease
T-Cell Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum Tolerated Dose of Carfilzomib

Maximum Tolerated Dose of Lenalidomide

Maximum Tolerated Dose of Romidepsin

Secondary outcome measures

Overall Response Rate (Orr) at the Maximum Tolerated Dose

Trial Design

1Treatment groups

Experimental Treatment

Group I: Carfilzomib, Romidepsin, LenalidomideExperimental Treatment3 Interventions

All patients will be treated with romidepsin administered intravenously on days 1 and 8 of a 21-day cycle. Lenalidomide will be taken orally daily for days 1-14 of a 21-day cycle. The carfilzomib will be given weekly on days 1, and 8 of a 21-day cycle.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Carfilzomib

2017

Completed Phase 3

~1440

Romidepsin

2011

Completed Phase 2

~790

Lenalidomide

2005

Completed Phase 3

~1480

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of NebraskaOTHER

539 Previous Clinical Trials

1,144,707 Total Patients Enrolled

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,865 Total Patients Enrolled

2 Trials studying Disease

1,044 Patients Enrolled for Disease

Steven Horwitz, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

6 Previous Clinical Trials

2,598 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this clinical experiment still open?

"Unfortuneately, this trial is currently not accepting participant enrollments. It was first posted on January 1st 2015 and the most recent update happened February 1st 2022. If you are searching for alternative studies, there are 1732 active trials involving lymphoma and T-cell patients, with 317 of them recruiting participants to test Romidepsin's effects."

Answered by AI

What illnesses have been shown to be alleviated by Romidepsin?

"Romidepsin is usually prescribed to those who have undergone two or more systemic chemotherapy regimens. It can also be beneficial in treating amyloidosis, refractory multiple myeloma, and relapsed/refractory multiple myeloma."

Answered by AI

How many individuals are being observed as part of this clinical investigation?

"At this time, the trial is not seeking participant enrollment. The clinical research was initially posted on January 1st 2015 and last modified February 1st 2022. If you search for other studies in lymphoma, t-cell or Romidepsin categories there are 1732 active trials currently admitting patients into their program."

Answered by AI

How many locations within this city have enrolled in the study?

"This clinical trial is taking place at 6 different locations, with Memorial Sloan Kettering Cancer Center in New york and Harrison as well as the Basking Ridge facility being a few prominent sites."

Answered by AI

Has any previous research been conducted on Romidepsin's efficacy?

"Currently, 317 clinical trials on Romidepsin are ongoing; 62 of those being Phase 3. While the bulk of research is situated in Chicago, Illinois, there are 14309 other sites which host studies for this medication."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

2015. "Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02341014.